Stockscreener 앱 받기
6.92
1.32%
0.09
시간 외 거래:
6.90
-0.02
-0.29%
전일 마감가:
$6.83
열려 있는:
$6.92
하루 거래량:
361.36K
Relative Volume:
1.18
시가총액:
$182.08M
수익:
$56.65M
순이익/손실:
$-53.31M
주가수익비율:
-3.3852
EPS:
-2.0442
순현금흐름:
$-40.75M
1주 성능:
-11.23%
1개월 성능:
-3.28%
6개월 성능:
-29.67%
1년 성능:
+45.07%
1일 변동 폭
$6.75
$7.23
1주일 범위
$6.69
$7.92
52주 변동 폭
$4.2993
$11.30
Cvrx Inc Stock (CVRX) Company Profile
명칭
Cvrx Inc
전화
(763) 416-2850
주소
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
6.92 | 179.71M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-01-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-11 | 재확인 | Lake Street | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2024-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Lake Street | Buy |
| 2022-07-18 | 개시 | Craig Hallum | Buy |
| 2021-07-26 | 개시 | Canaccord Genuity | Buy |
| 2021-07-26 | 개시 | Piper Sandler | Overweight |
| 2021-07-26 | 개시 | William Blair | Outperform |
모두보기
Cvrx Inc 주식(CVRX)의 최신 뉴스
CVRx Q1 Earnings Call Highlights - sharewise.com
CVRx Earnings Call Highlights Growth Amid Ongoing Losses - TipRanks
CVRX: Q1 2026 delivered strong revenue growth, margin expansion, and strategic progress in U.S. heart failure therapy - TradingView
CVRX: Q1 2026 revenue grew 20% with strong U.S. performance and improved gross margin - TradingView
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises By Investing.com - Investing.com Canada
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises - Investing.com
CVRx revenue rises 20 percent in first quarter as U.S. operations expand - Traders Union
CVRX Inc (NASDAQ:CVRX) Q1 2026 Earnings Meet Revenue Estimates, Loss Slightly Narrower Than Expected - ChartMill
CVRX ($CVRX) Releases Q1 2026 Earnings - Quiver Quantitative
CVRx: Q1 Earnings Snapshot - marketscreener.com
Medical device company CVRx, Inc. has released its performance guidance for fiscal year 2026. - Bitget
CVRx (CVRX) Q1 2026 Earnings Call Transcript - AOL.com
CVRx Reports First Quarter 2026 Financial and Operating Results - The Manila Times
CVRX: Q1 2026 revenue rose 20% year-over-year, with strong U.S. growth and improved gross margin - TradingView
CVRx's Q1 revenue rises 20%, beats expectations - TradingView
CVRx reports Q1 2026 revenue $14.8M, gross margin 87%, net loss $13.1M - TradingView
CVRx (NASDAQ: CVRX) grows Q1 2026 revenue 20% but remains loss-making - Stock Titan
CVRx heart device trial could expand Barostim patient pool threefold - Stock Titan
CVRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CVRx Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Earnings Preview: CVRx Inc to Report Financial Results Post-market on May 11 - 富途牛牛
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating - 富途牛牛
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14 - 富途牛牛
CVRx enrolls first patient in 2,500-patient heart failure trial By Investing.com - Investing.com South Africa
CVRx enrolls first patient in 2,500-patient heart failure trial - Investing.com
CVRx enrolls first patient in study of Barostim therapy for heart failure - MassDevice
CVRx launches landmark BENEFIT-HF trial for cardiac device research - Traders Union
A 2,500-patient heart failure study begins with device access at stake - Stock Titan
CVRx enrolls first patient in BENEFIT-HF trial to expand Barostim heart failure therapy use - Pluang
CVRx reports Barostim therapy boosts quality of life for heart failure patients - Traders Union
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Discipline and Rules-Based Execution in CVRX Response - Stock Traders Daily
Methodist University Hospital completes first Barostim implant with CVRx collaboration - Traders Union
Cantor Fitzgerald Maintains CVRx (CVRX) Overweight Recommendation - MSN
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026 - GlobeNewswire
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
CVRx promotes Barostim therapy as new option for heart failure patients at ISHLT2026 - Traders Union
CVRx reports preliminary 2025 results, issues 2026 guidance - MSN
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
CVRx nominates Michael Dale to board of directors By Investing.com - Investing.com India
CVRx nominates Michael Dale to board of directors - Investing.com
Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms - Traders Union
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors - marketscreener.com
Former Abbott structural heart leader Michael Dale lands CVRx board nomination - Stock Titan
CVRx (CVRX) details 2026 virtual meeting, board nominees and pay - Stock Titan
Behavioral Patterns of CVRX and Institutional Flows - Stock Traders Daily
CVRX Should I Buy - Intellectia AI
CVRx unveils Barostim session on neurohormonal targeting at ISHLT2026 - Traders Union
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Cvrx Inc (CVRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.34%
자본화:
|
볼륨(24시간):